Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label phase II study of the safety and efficacy of perifosine [KRX-0401; Keryx Pharmaceuticals] alone and in combination with dexamethasone for patients with relapsed or relapsed/refractory multiple myeloma.

Next Previous
X
Search
Trial Profile

An open-label phase II study of the safety and efficacy of perifosine [KRX-0401; Keryx Pharmaceuticals] alone and in combination with dexamethasone for patients with relapsed or relapsed/refractory multiple myeloma.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Perifosine (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors AEterna Zentaris Inc

    • Most Recent Events

    • 08 Jun 2011 Planned end date changed from 1 Dec 2009 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 04 Apr 2008 The estimated study completion date for this trial is now 1 Dec 2009, and the final data collection date for the primary outcome measure is July 2008, according to ClinicalTrials.gov.
    • 11 Dec 2007 Results presented at ASH 2007.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top